The Administration Core C will identify and accomplish administrative tasks related to the POl and facilitate the communication and dissemination of research data among the investigators. POl leadership will use Core C to facilitate the oversight ofthe research projects and cores. Core C will ensure effective and rapid communication and cooperation among investigators, projects, and cores. This core will also assist in sharing our research data with other investigators both within and outside of Memorial Sloan-Kettering Cancer Center (MSK) with a special emphasis to link Dr. Pao and the RP3 team at Vanderbilt and Dr. Sordella at the Cold Spring Harbor Laboratory with all facets of the program project through the POl intranet wiki and videoconferencing. The Administration Core C will provide: (1) administrative services;regulatory and reporting services, including preparation of annual reports and renewals;(2) budget management;(3) publication management and oversight;(4) wiki/intranet website management;(5) videoconferencing for all POl activities;(6) scheduling of POl """"""""work-in-progress"""""""" conferences for the investigators and yearly face-toface presentations to our advisory committees;and (6) support of the oversight activities of the Executive and Scientific Advisory committees. The Administration Core C centralizes, expands, and improves the operational capabilities of all the individual research projects and cores, avoids duplication, and ensures optimum utilization of resources. The MSK Lung POl Administrator supported by this Core will meet twice monthly with the Principal Investigators and quarterly with the Executive Committee to assist them in monitoring the status of operations so that the research supported by the grant proceeds as rapidly and efficiently as possible. The MSK Lung POl Administrator, working with the Principal Investigators, will prepare and distribute a yeariy progress report for the Executive and the Internal and External Scientific Advisory Committees to assist in their annual review and oversight. The Administration Core C supports the Principal Investigators, Executive Committee, Scientific Advisory Committees, research projects and other cores;and provides services that are essential for the POl to function as an integrated research program to develop new targets for treatment for persons with lung cancers.
Lung cancers are America's leading cancer killers, responsible for 158,000 deaths this year. This grant addresses the two most critical roadblocks to improving the care and curability of persons with these illnesses: (1) understanding how cancers spread (metastasis) and (2) the lack of highly effective medicines to prevent spread or to eradicate cancers that have spread from the lung. Core C is crifical to this effort.
|Yu, Helena A; Perez, Leslie; Chang, Qing et al. (2017) A Phase 1/2 Trial of Ruxolitinib and Erlotinib in Patients with EGFR-Mutant Lung Adenocarcinomas with Acquired Resistance to Erlotinib. J Thorac Oncol 12:102-109|
|Ichihara, Eiki; Westover, David; Meador, Catherine B et al. (2017) SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer. Cancer Res 77:2990-3000|
|Yaeger, Rona; Yao, Zhan; Hyman, David M et al. (2017) Mechanisms of Acquired Resistance to BRAF V600E Inhibition in Colon Cancers Converge on RAF Dimerization and Are Sensitive to Its Inhibition. Cancer Res 77:6513-6523|
|Weigelt, Britta; Comino-Méndez, Iñaki; de Bruijn, Ino et al. (2017) Diverse BRCA1 and BRCA2 Reversion Mutations in Circulating Cell-Free DNA of Therapy-Resistant Breast or Ovarian Cancer. Clin Cancer Res 23:6708-6720|
|Pal, Debjani; Pertot, Anja; Shirole, Nitin H et al. (2017) TGF-? reduces DNA ds-break repair mechanisms to heighten genetic diversity and adaptability of CD44+/CD24- cancer cells. Elife 6:|
|Yu, H A; Sima, C; Feldman, D et al. (2017) Phase 1 study of twice weekly pulse dose and daily low-dose erlotinib as initial treatment for patients with EGFR-mutant lung cancers. Ann Oncol 28:278-284|
|Boire, Adrienne; Zou, Yilong; Shieh, Jason et al. (2017) Complement Component 3 Adapts the Cerebrospinal Fluid for Leptomeningeal Metastasis. Cell 168:1101-1113.e13|
|Nieto, Patricia; Ambrogio, Chiara; Esteban-Burgos, Laura et al. (2017) A Braf kinase-inactive mutant induces lung adenocarcinoma. Nature 548:239-243|
|Yao, Zhan; Yaeger, Rona; Rodrik-Outmezguine, Vanessa S et al. (2017) Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS. Nature 548:234-238|
|Drilon, Alexander; Somwar, Romel; Wagner, Jacob P et al. (2016) A Novel Crizotinib-Resistant Solvent-Front Mutation Responsive to Cabozantinib Therapy in a Patient with ROS1-Rearranged Lung Cancer. Clin Cancer Res 22:2351-8|
Showing the most recent 10 out of 168 publications